In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
News|Articles|February 14, 2025
Supplements and Featured Publications
- Perspectives on FDA Oncology Approvals and Withdrawals That Shaped 2024: A Year in Review Roundup
- Volume 1
- Issue 1
Withdrawn Agents, Label Updates, and New Drug Formulations Shaped the Oncology Field in 2024
Author(s)Megan Hollasch
Fact checked by: Caroline Seymour
See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.
Advertisement
Advertisement
Precision medicine strengthened its place in cancer care in the US, with over 65 agents receiving accelerated, regular, or expanded approvals in 2024. But these weren’t the only game-changing indications the regulatory agency greenlit throughout the year—label updates, biosimilar approvals, and new formulations of drugs housed under accelerated, regular, or expanded pathways also changed practice.
Related to this article
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Advertisement
Advertisement